finance.yahoo.comNov 13$CTVA

Corteva Q3 Earnings Call Highlights

Corteva (CTVA) reported Q3 sales of $5.4B, down 1%, with operating EBITDA flat at $943M. Growth in North America, EMEA, and Asia Pacific offset pressure in Brazil, where market sellout was down 12% YTD. CEO Kissam discussed cost-cutting measures, including a hiring freeze and R&D project reviews. The company expects 2027 growth and share repurchases, with $1.8B cash on hand at Q3 end. New products Arylex and Pyraxalt saw over 20% volume growth, with combined annual revenue of $650M.

Original reporting

finance.yahoo.com

Published Nov 13, 2026, 5:14 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 13, 2026, 5:20 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Corteva Q3 Earnings Call Highlights — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$CTVANeutralMed

Why it matters

Earnings data provide a baseline for near‑term price action; investors will watch guidance and cash deployment plans.

Market read

First‑report earnings for a mid‑cap agribusiness, offering actionable insight for traders.

What to watch

Potential upside from new product volumes and upcoming cash deployment in 2027 may be underappreciated.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Corteva's Q3 earnings call highlighted mixed results: flat EBITDA, pricing headwinds, but volume growth and cost‑control measures.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CTVANeutralHigh confidence

Context

Corteva reported Q3 sales of $5.4B, flat EBITDA and pricing headwinds, providing fresh earnings data.

Expected impact

likely modest downside as market prices in pricing headwinds and flat EBITDA

Evidence & confidence

First‑report earnings numbers are material; flat EBITDA and $120M pricing headwind suggest limited upside.

Market effects

Sector

Agricultural chemicals sector may see pressure from pricing headwinds in North America.

Regional

Brazilian inventory concerns could affect regional ag‑input demand.

Global

Corteva's global volume growth offsets pricing declines, limiting broader market impact.

Counterpoint

What could challenge this read

Cost cuts and share repurchase plans could support the stock despite short‑term pricing pressure.

Key entities

Company
Corteva, Inc.
Agricultural science company reporting Q3 results.

Read at source ← All news

$CTVAMed

JP Morgan maintains Corteva at Overweight, lowers price target to $16 from $19

JP Morgan kept its Overweight rating on Corteva but reduced its price target from $19 to $16, a 15.8% cut. The new target suggests a 74.1% upside from the Nov 12 close of $9.19, according to the bank.

tradingview.comNov 13

$SMCIMed

Why SMCI, Corteva, and Global Payments Shares Dropped

Super Micro Computer (SMCI) shares fell 11.30% to $26.99 amid DOJ probe concerns. Corteva (CTVA) lost 24% after Q3 revenue dropped 8.6% Y/Y to $1.59B due to Brazil market pressures. Global Payments (GPN) dropped 12.01% below $90 after buyout talks collapsed.

baystreet.caNov 13

$CTVAHigh

Oppenheimer downgrades Corteva stock rating on execution challenges

Oppenheimer downgraded Corteva (CTVA) to Perform from Outperform, removing its $17 price target. The stock fell 23% to $9.19. CTVA missed Q3 2026 earnings, reporting $0.06 EPS on $1.59B revenue vs. estimates of $0.10 EPS on $1.77B revenue. Oppenheimer cited execution challenges and industry-wide factors for the miss, noting Brazil headwinds may be transitory.

investing.comNov 13

$CTVAMedAI 8/10

Corteva Inc (CTVA) Q3 2026 Earnings Call Transcript

Corteva Inc. (CTVA) reported Q3 2026 earnings, with net sales at $1.6B, down 9% YoY, and operating EBITDA at $222M, down 17%. Growth was seen in North America, EMEA, and Asia Pacific, but Latin America sales dropped 31% due to market challenges. The company maintained flat EBITDA levels YoY and expanded margins despite $230M in pricing headwinds. Corteva declared its first quarterly dividend and remains on track for a year-end cash position of $1.5B.

finance.yahoo.comNov 12

$CTVAHighAI 9/10

Why is Corteva stock plunging today?

Corteva stock fell 18.8% to $9.86, hitting a 52-week low of $9.14, after Q3 results missed estimates and the company cut its 2026 profit outlook, citing Brazil's agricultural chemicals market. Adjusted EPS was $0.06 vs. $0.10 estimate, and revenue was $1.59B, down 9% YoY. The company was also removed from the MSCI USA Index, adding to selling pressure.

investing.comNov 12

$CTVAHighAI 8/10

Why Corteva Stock Dropped on Thursday

Corteva (CTVA) shares fell 20.2% after Q3 earnings missed estimates. The company reported $0.06 EPS and $1.6B revenue, citing price declines in agricultural chemicals. Revenue grew in North America, Europe, and Asia but dropped 28% in Latin America. Corteva expects challenging market conditions, particularly in Brazil.